| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BCP.2010.09.023 |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:S0006295210007215?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:S0006295210007215?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 20920481 |
| P2093 | author name string | Beverly A. Teicher | |
| P2860 | cites work | BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy | Q27650860 |
| Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases | Q27657708 | ||
| Therapeutic antibody targeting of individual Notch receptors | Q27660544 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2 | Q28570936 | ||
| Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. | Q37500943 | ||
| Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. | Q37502702 | ||
| Drug resistance associated with antiangiogenesis therapy | Q37518288 | ||
| Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors | Q37539304 | ||
| Breast cancer: beyond the cutting edge | Q37598890 | ||
| Antiangiogenic therapies in breast cancer | Q37639970 | ||
| Impact of anti-angiogenic treatments on metastatic renal cell carcinoma | Q37642792 | ||
| Platelet-derived growth factor receptors regulate mesenchymal stem cell fate: implications for neovascularization | Q37676215 | ||
| VEGF-A: a critical regulator of blood vessel growth | Q37694868 | ||
| Current status and future prospects for anti-angiogenic therapies in cancer. | Q38088366 | ||
| Hepatocyte growth factor induced up-regulations of VEGF through Egr-1 in hepatocellular carcinoma cells | Q38353151 | ||
| PlGF blockade does not inhibit angiogenesis during primary tumor growth | Q39718360 | ||
| Placenta growth factor is a survival factor for human malignant mesothelioma cells | Q39841354 | ||
| CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer | Q39853277 | ||
| NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells | Q39880907 | ||
| Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients | Q39881982 | ||
| Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts | Q39967256 | ||
| A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker | Q40001486 | ||
| Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma | Q40275475 | ||
| Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors | Q43054611 | ||
| Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis | Q43072819 | ||
| Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. | Q43142299 | ||
| Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio | Q43282877 | ||
| Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors | Q44649604 | ||
| Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma | Q46052750 | ||
| Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor | Q46470663 | ||
| Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients | Q46781791 | ||
| PlGF expression in pre-invasive and invasive lesions of uterine cervix is associated with angiogenesis and lymphangiogenesis. | Q53305472 | ||
| Protective effect of an inhibitor of interleukin-8 (meraxin) from ischemia and reperfusion injury in a rat model of kidney transplantation. | Q53535148 | ||
| Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. | Q54504889 | ||
| Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease | Q57983635 | ||
| The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth | Q80212331 | ||
| Placenta growth factor expression has prognostic value in malignant pleural mesothelioma | Q84292418 | ||
| Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis | Q28593488 | ||
| Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma | Q30434154 | ||
| Chemokines as mediators of neovascularization | Q30438032 | ||
| Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization | Q33362774 | ||
| Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer | Q33385748 | ||
| Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance | Q33627739 | ||
| Bevacizumab and breast cancer: current therapeutic progress and future perspectives | Q33640753 | ||
| Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. | Q33710574 | ||
| Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. | Q33773569 | ||
| Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis | Q34022315 | ||
| CXCL12 (SDF-1)/CXCR4 pathway in cancer | Q34116260 | ||
| Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis | Q34512415 | ||
| Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules | Q35684358 | ||
| The FGF family: biology, pathophysiology and therapy | Q36933339 | ||
| Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials | Q37008436 | ||
| Inflammation, inflammatory cells and angiogenesis: decisions and indecisions | Q37035029 | ||
| Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis | Q37062140 | ||
| G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models | Q37149710 | ||
| The discovery of the placental growth factor and its role in angiogenesis: a historical review | Q37196288 | ||
| Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. | Q37234638 | ||
| Rational targeting of Notch signaling in cancer | Q37256451 | ||
| Notch signaling regulates tumor angiogenesis by diverse mechanisms | Q37256455 | ||
| FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? | Q37333639 | ||
| Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways | Q37356314 | ||
| Early development of sunitinib in hepatocellular carcinoma | Q37357314 | ||
| Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature | Q37363751 | ||
| Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts | Q37364840 | ||
| Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies | Q37382152 | ||
| Positive and negative modulation of angiogenesis by VEGFR1 ligands | Q37401612 | ||
| Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications | Q37410402 | ||
| Novel therapeutic inhibitors of the c-Met signaling pathway in cancer | Q37422804 | ||
| When the sphingosine kinase 1/sphingosine 1-phosphate pathway meets hypoxia signaling: new targets for cancer therapy. | Q37454105 | ||
| Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma | Q37463927 | ||
| Anticancer strategies involving the vasculature | Q37474318 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angiogenesis inhibitor | Q574834 |
| P304 | page(s) | 6-12 | |
| P577 | publication date | 2010-10-12 | |
| P1433 | published in | Biochemical Pharmacology | Q864229 |
| P1476 | title | Antiangiogenic agents and targets: A perspective | |
| P478 | volume | 81 |
| Q34874678 | Aberrant proliferation in CXCR7+ endothelial cells via degradation of the retinoblastoma protein. |
| Q38000872 | Advances in the systemic treatment of cutaneous sarcomas |
| Q36563542 | Antiangiogenic therapy for cancer: an update |
| Q36881812 | Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy |
| Q51843632 | Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway. |
| Q54475869 | De novo design of N-(pyridin-4-ylmethyl)aniline derivatives as KDR inhibitors: 3D-QSAR, molecular fragment replacement, protein-ligand interaction fingerprint, and ADMET prediction. |
| Q37604560 | Discovery and functional assessment of gene variants in the vascular endothelial growth factor pathway |
| Q41062063 | Endostatin enhances antitumor effect of tumor antigen-pulsed dendritic cell therapy in mouse xenograft model of lung carcinoma |
| Q37843943 | Hypoxia-mediated biological control |
| Q33738607 | In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors |
| Q26752752 | Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next? |
| Q38025261 | Modeling and predicting clinical efficacy for drugs targeting the tumor milieu |
| Q58701885 | Modulation of the Tumor Microenvironment by CXCR4 Antagonist-Armed Viral Oncotherapy Enhances the Antitumor Efficacy of Dendritic Cell Vaccines against Neuroblastoma in Syngeneic Mice |
| Q92835893 | Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma |
| Q36220942 | Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach |
| Q35837949 | Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways |
| Q37502464 | Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy |
| Q33654212 | Silencing of Jagged1 inhibits cell growth and invasion in colorectal cancer |
| Q34678040 | Sphingosine‐1‐phosphate antibodies as potential agents in the treatment of cancer and age‐related macular degeneration |
| Q35122891 | The cytochrome P450 4A/F-20-hydroxyeicosatetraenoic acid system: a regulator of endothelial precursor cells derived from human umbilical cord blood |
| Q35067624 | The intricate role of CXCR4 in cancer |
| Q36741686 | c-MET inhibition enhances the response of the colorectal cancer cells to irradiation in vitro and in vivo |
Search more.